Zhang Xinyu, Tao Xiaoxuan, Zhou Yuxin, Shi Guangyue, Wang Tianjiao
Department of Internal Medicine-Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, People's Republic of China.
Department of Radiotherapy, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, People's Republic of China.
Cancer Manag Res. 2024 Sep 30;16:1305-1319. doi: 10.2147/CMAR.S467817. eCollection 2024.
Bladder carcinoma (BLCA) is characterized by high morbidity, mortality, and treatment costs. Breast cancer gene 1 (BRCA1), a tumor suppressor gene, inhibits the development of malignant tumors. However, research on the significance of BRCA1 in BLCA is limited. This study aims to explore the importance of BRCA1 in BLCA using bioinformatic methods and immunohistochemistry.
Gene expression, clinical, and survival data were collected from the TCGA databases through the UCSC Xena platform (http://xena.ucsc.edu/). The TPM data from the TCGA and GETEx databases were integrated using the GEPIA database (http://GEPIA.cancer-pku.cn). The study then explored the differential expression, survival prognosis, functional enrichment, and immune cell infiltration analyses of BRCA1 in BLCA. A PPI network of BRCA1 was constructed using the STRING database, and a BRCA1-associated gene-gene interaction network was generated using the GeneMANIA database. Immunohistochemistry (IHC) assays were performed to verify the expression levels of BRCA1 in bladder tumour tissues and adjacent normal tissues.
BRCA1 is associated with BLCA. Differential analysis indicated that BRCA1 acts as a risk factor for BLCA but does not show significant expression differences across genders, stages, tumor stages, lymph node stages, or metastasis stages. Additionally, staging was based on the eighth edition of the American Joint Committee on Cancer (AJCC) for BLCA. Co-expression network and Gene Set Enrichment Analysis (GESA) confirmed that BRCA1 is involved in various BLCA pathways. Furthermore, BRCA1 expression was also linked to immune cell infiltration. However, survival prognosis analysis revealed no significant correlation between the prognosis of BLCA and BRCA1.
We demonstrated that BRCA1 is a prospective predicted and immunological biomarker in BLCA, offering new avenues for potential therapies.
膀胱癌（BLCA）具有高发病率、高死亡率和高治疗成本的特点。乳腺癌1号基因（BRCA1）作为一种肿瘤抑制基因，可抑制恶性肿瘤的发展。然而，关于BRCA1在膀胱癌中的意义的研究有限。本研究旨在利用生物信息学方法和免疫组织化学探讨BRCA1在膀胱癌中的重要性。
BRCA1与膀胱癌相关。差异分析表明，BRCA1是膀胱癌的一个危险因素，但在性别、分期、肿瘤分期、淋巴结分期或转移分期方面未显示出显著的表达差异。此外，分期基于美国癌症联合委员会（AJCC）第八版膀胱癌分期标准。共表达网络和基因集富集分析（GESA）证实BRCA1参与了多种膀胱癌相关通路。此外，BRCA1表达还与免疫细胞浸润有关。然而，生存预后分析显示膀胱癌预后与BRCA1之间无显著相关性。
我们证明BRCA1是膀胱癌中一种有前景的预测性和免疫生物标志物，为潜在治疗提供了新途径。
